CLINICAL TRIALS PROFILE FOR LINZESS

All Clinical Trials for Linzess

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00730171 ↗	An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation	Completed	Forest Laboratories	Phase 3	2008-09-01	The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
NCT00730171 ↗	An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation	Completed	Ironwood Pharmaceuticals, Inc.	Phase 3	2008-09-01	The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
NCT00765999 ↗	An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation	Completed	Ironwood Pharmaceuticals, Inc.	Phase 3	2008-10-31	The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
NCT00765999 ↗	An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation	Completed	Forest Laboratories	Phase 3	2008-10-31	The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
NCT01950403 ↗	Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers	Completed	National Cancer Institute (NCI)	Phase 1	2013-09-01	This randomized phase I trial studies the side effects and best dose of linaclotide acetate in preventing colorectal cancer in healthy volunteers. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of linaclotide acetate may prevent colorectal cancer.
NCT01950403 ↗	Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers	Completed	Mayo Clinic	Phase 1	2013-09-01	This randomized phase I trial studies the side effects and best dose of linaclotide acetate in preventing colorectal cancer in healthy volunteers. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of linaclotide acetate may prevent colorectal cancer.

Clinical Trial Conditions for Linzess

Condition Name

Condition Name for Linzess
Intervention	Trials
Irritable Bowel Syndrome With Constipation	5
Chronic Idiopathic Constipation	4
Chronic Constipation	3
Barrett Esophagus	1

Condition MeSH

Condition MeSH for Linzess
Intervention	Trials
Constipation	15
Irritable Bowel Syndrome	8
Syndrome	7
Colorectal Neoplasms	2

Clinical Trial Locations for Linzess

Trials by Country

Trials by Country for Linzess
Location	Trials
United States	280
Canada	8
Germany	3
Croatia	3
United Kingdom	3

Trials by US State

Trials by US State for Linzess
Location	Trials
Pennsylvania	12
Texas	11
Ohio	10
Florida	10
California	10

Clinical Trial Progress for Linzess

Clinical Trial Phase

Clinical Trial Phase for Linzess
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	5
Phase 2	6

Clinical Trial Status

Clinical Trial Status for Linzess
Clinical Trial Phase	Trials
Completed	11
Recruiting	3
Not yet recruiting	2

Clinical Trial Sponsors for Linzess

Sponsor Name

Sponsor Name for Linzess
Sponsor	Trials
Ironwood Pharmaceuticals, Inc.	10
Forest Laboratories	9
Forest Laboratories, LLC, an Allergan Affiliate	2

Sponsor Type

Sponsor Type for Linzess
Sponsor	Trials
Industry	24
Other	6
NIH	2